United Therapeutics Corp. (UTHR)
541.70
-29.68
(-5.19%)
USD |
NASDAQ |
Oct 02, 16:00
537.12
-4.58
(-0.85%)
After-Hours: 20:00
United Therapeutics Enterprise Value : 20.46B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 20.46B |
| October 01, 2026 | 21.72B |
| September 30, 2026 | 20.46B |
| September 29, 2026 | 17.89B |
| September 28, 2026 | 18.06B |
| September 25, 2026 | 17.63B |
| September 24, 2026 | 17.49B |
| September 23, 2026 | 18.22B |
| September 22, 2026 | 18.57B |
| September 21, 2026 | 18.38B |
| September 18, 2026 | 18.45B |
| September 17, 2026 | 18.56B |
| September 16, 2026 | 18.61B |
| September 15, 2026 | 18.69B |
| September 14, 2026 | 18.79B |
| September 11, 2026 | 18.55B |
| September 10, 2026 | 18.84B |
| September 09, 2026 | 18.97B |
| September 08, 2026 | 18.59B |
| September 04, 2026 | 18.15B |
| September 03, 2026 | 18.26B |
| September 02, 2026 | 18.34B |
| September 01, 2026 | 19.22B |
| August 31, 2026 | 19.12B |
| August 28, 2026 | 19.34B |
| Date | Value |
|---|---|
| August 27, 2026 | 19.87B |
| August 26, 2026 | 19.39B |
| August 25, 2026 | 19.47B |
| August 24, 2026 | 19.23B |
| August 21, 2026 | 19.24B |
| August 20, 2026 | 19.57B |
| August 19, 2026 | 19.92B |
| August 18, 2026 | 19.46B |
| August 17, 2026 | 19.04B |
| August 14, 2026 | 18.66B |
| August 13, 2026 | 18.73B |
| August 12, 2026 | 19.18B |
| August 11, 2026 | 19.34B |
| August 10, 2026 | 19.94B |
| August 07, 2026 | 20.33B |
| August 06, 2026 | 20.08B |
| August 05, 2026 | 19.49B |
| August 04, 2026 | 19.47B |
| August 03, 2026 | 19.37B |
| July 31, 2026 | 19.43B |
| July 30, 2026 | 19.78B |
| July 29, 2026 | 19.73B |
| July 28, 2026 | 19.68B |
| July 27, 2026 | 19.87B |
| July 24, 2026 | 19.89B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Liquidia Corp. | 2.451B |
| MannKind Corp. | 1.503B |
| Insmed, Inc. | 23.84B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 333.00M |
| Revenue (Quarterly) | 783.30M |
| Total Expenses (Quarterly) | 450.30M |
| EPS Diluted (Quarterly) | 7.271 |
| Gross Profit Margin (Quarterly) | 87.30% |
| Profit Margin (Quarterly) | 42.51% |
| Earnings Yield | 5.16% |
| Operating Earnings Yield | 5.52% |
| Normalized Earnings Yield | 4.816 |